Current practices in menstrual management in adolescents with cancer: A national survey of pediatric oncology providers.
hematology/oncology general
medical oncology
pediatric hematology/oncology
support care
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
17
05
2019
revised:
23
06
2019
accepted:
14
07
2019
pubmed:
24
8
2019
medline:
17
3
2020
entrez:
24
8
2019
Statut:
ppublish
Résumé
Adolescents and young adult (AYA) women with cancer are at risk of heavy menstrual bleeding (HMB) due to thrombocytopenia, coagulopathy, and/or disruption of the hypothalamic-pituitary-gonadal axis. Currently, little is known about current practices to help prevent and treat HMB in AYA women with cancer. We surveyed providers from 100 pediatric oncology centers. Face and content validity were assessed prior to distribution. Descriptive statistics, Chi-squared and Fisher exact tests were used for analysis. Ninety-four percent of respondents have recommended preventative menstrual suppression. More than half of respondents agreed that patients with the following types of cancers should receive preventative menstrual suppression: sarcomas, acute leukemias, lymphomas, and germ cell tumors. The most preferred form of menstrual suppression was GnRH agonists. Almost 95% of respondents felt that it is important to consider menstrual suppression and that a formal guideline about initiation of menstrual suppression would be helpful. Only 46% felt comfortable personally managing menstrual suppression. The vast majority of pediatric oncologists who responded to this national survey have used preventative menstrual suppression and feel that it is important to consider in many types of AYA cancers. Although pediatric oncologists are most often managing menstrual suppression, they do not feel comfortable doing so and desire guidelines to help with management. Future studies to assess which patients require menstrual suppression and which menstrual suppression is best tolerated and efficacious is needed.
Sections du résumé
BACKGROUND
Adolescents and young adult (AYA) women with cancer are at risk of heavy menstrual bleeding (HMB) due to thrombocytopenia, coagulopathy, and/or disruption of the hypothalamic-pituitary-gonadal axis. Currently, little is known about current practices to help prevent and treat HMB in AYA women with cancer.
METHODS
We surveyed providers from 100 pediatric oncology centers. Face and content validity were assessed prior to distribution. Descriptive statistics, Chi-squared and Fisher exact tests were used for analysis.
RESULTS
Ninety-four percent of respondents have recommended preventative menstrual suppression. More than half of respondents agreed that patients with the following types of cancers should receive preventative menstrual suppression: sarcomas, acute leukemias, lymphomas, and germ cell tumors. The most preferred form of menstrual suppression was GnRH agonists. Almost 95% of respondents felt that it is important to consider menstrual suppression and that a formal guideline about initiation of menstrual suppression would be helpful. Only 46% felt comfortable personally managing menstrual suppression.
CONCLUSIONS
The vast majority of pediatric oncologists who responded to this national survey have used preventative menstrual suppression and feel that it is important to consider in many types of AYA cancers. Although pediatric oncologists are most often managing menstrual suppression, they do not feel comfortable doing so and desire guidelines to help with management. Future studies to assess which patients require menstrual suppression and which menstrual suppression is best tolerated and efficacious is needed.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27961Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
American College of Obstetricians and Gynecologists. Options for prevention and management of heavy menstrual bleeding in adolescent patients undergoing cancer treatment. ACOG Committee Opinion No. 606. Obstet Gynecol. 2014;124(2):397-402.
Meirow D, Rabinovici J, Katz D, Or R, Shufaro Y, Ben-Yehuda D. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer. 2006;107(7):1634-1641.
Dasararaju R, Marques MB. Adverse effects of transfusion. Cancer Control. 2015;22(1):16-25.
Nagaharu K, Sugimoto Y, Hoshi Y, et al. Persistent symptomatic parvovirus B19 infection with severe thrombocytopenia transmitted by red blood cell transfusion containing low parvovirus B19 DNA levels. Transfusion. 2017;57(6):1414-1418.
Haesebaert J, Benet T, Michallet M, Vanhems P. Septic shock during platelet transfusion in a patient with acute myeloid leukaemia. BMJ Case Rep. 2013;2013. pii: bcr2013010412.
Bhuva DK, Vachhani JH. Red cell alloimmunization in repeatedly transfused patients. Asian J Transfus Sci. 2017;11(2):115-120.
Louie M, Wright K, Siedhoff MT. The case against endometrial ablation for treatment of heavy menstrual bleeding. Curr Opin Obstet Gynecol. 2018;30(4):287-292.
Kafy S, Huang JY, Al-Sunaidi M, Wiener D, Tulandi T. Audit of morbidity and mortality rates of 1792 hysterectomies. J Minim Invasive Gynecol. 2006;13(1):55-59.
Quaas AM, Ginsburg ES. Prevention and treatment of uterine bleeding in hematologic malignancy. Eur J Obstet Gynecol Reprod Biol. 2007;134(1):3-8.
Adegite EA, Goyal RK, Murray PJ, Marshal M, Sucato GS. The management of menstrual suppression and uterine bleeding: a survey of current practices in the Pediatric Blood and Marrow Transplant Consortium. Pediatr Blood Cancer. 2012;59(3):553-557.
Smith F. Clinical practice guidelines. Pediatric Blood and Marrow Transplant Consortium; September 2002. A copy can be obtained by contacting A. Close.
Polit DF, Beck CT, Owen SV. Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. Res Nurs Health. 2007;30(4):459-467.
Waltz CF, StricklandOL, Lenz ER. Measurement in nursing and health research. 3rd ed. New York, NY: Springer; 2005.
Streur CS, Schafer CL, Garcia VP, Wittmann DA. “I don't know what I'm doing… I hope I'm not just an idiot”: the need to train pediatric urologists to discuss sexual and reproductive health care with young women with spina bifida. J Sex Med. 2018;15(10):1403-1413.
Kazmerski TM, Borrero S, Tuchman LK, et al. Provider and patient attitudes regarding sexual health in young women with cystic fibrosis. Pediatrics. 2016;137(6). pii: e20154452.
Kazmerski TM, Tuchman LK, Borrero S, et al. Cystic fibrosis program directors' attitudes toward sexual and reproductive health in young women with CF. Pediatr Pulmonol. 2016;51(1):22-27.
Smith-Whitley K. Reproductive issues in sickle cell disease. Hematology. 2014;1:418-424.
Frederick NN, Campbell K, Kenney LB, Moss K, Speckhart A, Bober SL. Barriers and facilitators to sexual and reproductive health communication between pediatric oncology clinicians and adolescent and young adult patients: the clinician perspective. Pediatr Blood Cancer. 2018;65(8):e27087.
Kirkham YA, Ornstein MP, Aggarwal A, McQuillan S, Canpago C. Menstrual suppression in special circumstances. J Obstet Gynaecol Can. 2014;36(10):915-924.
Quinn SM, Louis-Jacques J. Menstrual management and reproductive concerns in adolescent and young adult women with underlying hematologic or oncologic disease. Curr Opin Pediatr. 2016;28(4):421-427.
Chang BH, Edelman A, Godder K. Management of menstrual bleeding and cycle control after hematopoietic stem cell transplant. Int J Gynaecol Obstet. 2008;100(1):76-77.
Chang K, Merideth MA, Stratton P. Hormone use for therapeutic amenorrhea and contraception during hematopoietic cell transplantation. Obstet Gynecol. 2015;126(4):779-784.
Chiusolo P, Salutari P, Sica S, et al. Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. Bone Marrow Transplant. 1998;21(8):821-823.
Poorvu PD, Barton SE, Duncan CN, et al. Use and effectiveness of gonadotropin-releasing hormone agonists for prophylactic menstrual suppression in postmenarchal women who undergo hematopoietic cell transplantation. J Pediatr Adolesc Gynecol. 2016;29(3):265-268.
Sica S, Salutari P, Di Mario A, et al. Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. Am J Hematol. 1996;51(3):248-249.
WHO. Medical eligibility criteria for contraceptive use. A WHO family planning cornerstone. 5th ed. Geneva: World Health Organization; 2015.
Browne H, Manipalviratn S, Armstrong A. Using an intrauterine device in immunocompromised women. Obstet Gynecol. 2008;112(3):667-669.
Morrison CS, Sekadde-Kigondu C, Sinei SK, Weiner DH, Kwok C, Kokonya D. Is the intrauterine device appropriate contraception for HIV-1-infected women. BJOG. 2001;108(8):784-790.
Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197(2):144. e141-148.
Krajewski CM, Geetha D, Gomez-Lobo V. Contraceptive options for women with a history of solid-organ transplantation. Transplantation. 2013;95(10):1183-1186.
Ramhendar T, Byrne P. Use of the levonorgestrel-releasing intrauterine system in renal transplant recipients: a retrospective case review. Contraception. 2012;86(3):288-289.
Nizamic TAA, Debiec K, Smith J, Micks E, Prager S. Safety and efficacy of the levonorgestrel-releasing intrauterine system in transplant patients [abstract]. Am J Transplant. 2013;13(suppl 5). https://atcmeetingabstracts.com/abstract/safety-and-efficacy-of-the-levonorgestrel-releasing-intrauterine-system-in-transplant-patients/. Accessed February 14, 2019.
Chi C, Huq FY, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception. 2011;83(3):242-247.
Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG. 2004;111(12):1425-1428.
Lethaby A HM, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2015(4):CD002126.
Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91(3):694-697.
Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269-276.
Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29(17):2334-2341.
Kim SS, Lee JR, Jee BC, et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol. 2010;53(4):740-752.
Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat. 2008;110(3):411-416.
Senra JC, Roque M, Talim MCT, Reis FM, Tavares RLC. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018;51(1):77-86.